Evidence map›Paper›PMID 26416271›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

Continuous Antigenic Stimulation of DO11.10 TCR Transgenic Mice in the Presence or Absence of IL-1β: Possible Implications for Mechanisms of T Cell Depletion in HIV Disease.

Kristin Ladell, Mette D Hazenberg, Mark Fitch, Claire Emson, Bridget K McEvoy-Hein Asgarian, Jeff E Mold, Corey Miller, Robert Busch, David A Price, Marc K Hellerstein and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Kristin LadellDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110; mike.mccune@ucsf.edu ladellk@gmail.com.
Mette D HazenbergDepartment of Immunology, University Medical Center Utrecht, 3584 EA Utrecht, the Netherlands;
Mark FitchDepartment of Nutritional Sciences, University of California, Berkeley, Berkeley, CA 94720;
Claire EmsonDepartment of Nutritional Sciences, University of California, Berkeley, Berkeley, CA 94720; KineMed Inc., Emeryville, CA 94608;
Bridget K McEvoy-Hein AsgarianDepartment of Nutritional Sciences, University of California, Berkeley, Berkeley, CA 94720;
Jeff E MoldDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110;
Corey MillerDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110;
Robert BuschDepartment of Life Sciences, Whitelands College, University of Roehampton, London SW15 4JD, United Kingdom;
David A PriceInstitute of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, United Kingdom; and Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Marc K HellersteinDepartment of Nutritional Sciences, University of California, Berkeley, Berkeley, CA 94720; KineMed Inc., Emeryville, CA 94608;
Joseph M McCuneDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110; mike.mccune@ucsf.edu ladellk@gmail.com.
University of California, San Francisco · USUniversity of California, Berkeley · USKineMed (United States) · USNational Institutes of Health · USUniversity Medical Center Utrecht · NLUniversity of Roehampton · GB

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
CTSA: K12 COMPONENTKL2RR024130 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$19.3M
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0M
HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEMR37AI040312 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCUNE, JOSEPH M · 2000 to 2010
$5.0M
NIH Director's Pioneer Award (RMI)DP1OD000329 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCUNE, JOSEPH M · 2004 to 2008
$4.2M
THYMIC FUNCTION IN ADULTS WITH HIV1 DISEASER01AI043864 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI MCCUNE, JOSEPH M · 1999 to 2002
$1.2M
T CELL KINETICS AND SOURCES--EFFECTS OF HIV AND THERAPYR01AI043866 · NIAID · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI HELLERSTEIN, MARC KOPEL · 1999 to 2002
$849k
HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEM IN VIVOR01AI040312 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI MCCUNE, JOSEPH M · 1996 to 1999
–
NCRR NIH HHS KL2 RR024130NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR024131-01NIAID NIH HHS R01 AI040312NIAID NIH HHS R01 AI043864NIAID NIH HHS R01 AI043866NIAID NIH HHS R01 AI43866NIAID NIH HHS R37 AI040312NIAID NIH HHS R37 AI40312NIAID NIH HHS T32 AI007334NIAID NIH HHS U01 AI43641NIH HHS DP1 OD000329NIH HHS DPI OD00329Wellcome Trust 093053Wellcome Trust 100326
6 · The paper itself

Abstract

Untreated HIV disease is associated with chronic immune activation and CD4(+) T cell depletion. A variety of mechanisms have been invoked to account for CD4(+) T cell depletion in this setting, but the quantitative contributions of these proposed mechanisms over time remain unclear. We turned to the DO11.10 TCR transgenic mouse model, where OVA is recognized in the context of H-2(d), to explore the impact of chronic antigenic stimulation on CD4(+) T cell dynamics. To model dichotomous states of persistent Ag exposure in the presence or absence of proinflammatory stimulation, we administered OVA peptide to these mice on a continuous basis with or without the prototypic proinflammatory cytokine, IL-1β. In both cases, circulating Ag-specific CD4(+) T cells were depleted. However, in the absence of IL-1β, there was limited proliferation and effector/memory conversion of Ag-specific T cells, depletion of peripheral CD4(+) T cells in hematolymphoid organs, and systemic induction of regulatory Foxp3(+)CD4(+) T cells, as often observed in late-stage HIV disease. By contrast, when OVA peptide was administered in the presence of IL-1β, effector/memory phenotype T cells expanded and the typical symptoms of heightened immune activation were observed. Acknowledging the imperfect and incomplete relationship between Ag-stimulated DO11.10 TCR transgenic mice and HIV-infected humans, our data suggest that CD4(+) T cell depletion in the setting of HIV disease may reflect, at least in part, chronic Ag exposure in the absence of proinflammatory signals and/or appropriate APC functions.

Indexed as

Amino Acid SequenceAnimalsCD4-Positive T-LymphocytesFemaleHIV InfectionsInterleukin-1betaLymph NodesLymphocyte ActivationMaleMiceMice, TransgenicMolecular Sequence DataOvalbuminSpleenT-Lymphocytes, RegulatoryInterleukin-1betaOvalbumin

Identifiers

PMID26416271
PMCPMC4610874
OpenAlexW2303945748

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.